Replies to post #928 on Bristol Myers Squibb (BMY)

[DewDiligence]

Zeposia hits primary/secondary endpoints in UC phase-3:

https://www.businesswire.com/news/home/20200602005291/en

-Bristol Myers Squibb (NYSE:BMY) today announced results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with moderate to severe ulcerative colitis. True North met both primary endpoints, demonstrating highly statistically significant (p-value < 0.0001) results for induction of clinical remission at Week 10 and in maintenance at Week 52. The study also met key secondary endpoints of clinical response and endoscopic improvement in induction at Week 10 and in maintenance at Week 52.